Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rumsey

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Bioorganic & Medicinal Chemistry Letters|September 30, 2011
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent regionRobert O Hughes, Todd Maddux, D Joseph Rogier, et al.
Science (New York, N.Y.)|April 21, 2018
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2AAgostinho G Rocha, Antonietta Franco, Andrzej M Krezel, et al.
Brain Stimulation|February 6, 2018
Rigor and reproducibility in research with transcranial electrical stimulation: An NIMH-sponsored workshopMarom Bikson, Andre R Brunoni, Leigh E Charvet, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneRobert O Hughes, John K Walker, D Joseph Rogier, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
Brain : a Journal of Neurology|April 13, 2011
Harnessing neuroplasticity for clinical applicationsSteven C Cramer, Mriganka Sur, Bruce H Dobkin, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Bioorganic & Medicinal Chemistry Letters|September 30, 2011
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent regionRobert O Hughes, Todd Maddux, D Joseph Rogier, et al.
Science (New York, N.Y.)|April 21, 2018
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2AAgostinho G Rocha, Antonietta Franco, Andrzej M Krezel, et al.
Brain Stimulation|February 6, 2018
Rigor and reproducibility in research with transcranial electrical stimulation: An NIMH-sponsored workshopMarom Bikson, Andre R Brunoni, Leigh E Charvet, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneRobert O Hughes, John K Walker, D Joseph Rogier, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
Brain : a Journal of Neurology|April 13, 2011
Harnessing neuroplasticity for clinical applicationsSteven C Cramer, Mriganka Sur, Bruce H Dobkin, et al.
Pageof 7